Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in pulmonary hypertension associated with left ventricular systolic dysfunction
2009-015878-35Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) and heart failure with reduced ejection fraction (HFrEF) comparing Riociguat with Placebo (2 arms). Primary endpoint: Change from baseline in mean pulmonary arterial pressure at rest. Started Jan 2010; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension (PH)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2009-015878-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015878-35.